Efficacy and Safety of Telitacicept in Adult Immunoglobulin A Vasculitis Nephropathy Patients with Persistent Proteinuria

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

Abstract Title *

Efficacy and Safety of Telitacicept in Adult Immunoglobulin A Vasculitis Nephropathy Patients with Persistent Proteinuria

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Ran Zhang 315860158@qq.com Nanchang University The Second Affiliated Hospital Nanchang China *

Co-author 2

Gaosi Xu gaosixu@163.com Nanchang University The Second Affiliated Hospital Nanchang China -

Co-author 3

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

To investigate the efficacy and safety of telitacicept in adult immunoglobulin A vasculitis nephritis (IgAVN) patients with persistent proteinuria.

Methods

This prospective single-arm study enrolled patients aged ≥ 18 years diagnosed with IgAVN, an eGFR > 60 mL/min/1.73m², previously received previous treatment with corticosteroids and immunosuppressants or had contraindications intolerance to the use of corticosteroids and immunosuppressants, and a 24-hour urinary protein creatinine ratio (UPCR) > 1 g/g. Patients received telitacicept 160 mg weekly for 6 months.

Results

A total of 13 patients were enrolled in this study, in which 7 patients were males. The mean age of patients was 35 years (Table 1). The mean time since diagnosis before telitacicept treatment was 12.6 months. After 6 months of treatment with telitacicept, the mean 24-hour UPCR decreased from a baseline value of 2.9 ± 0.8 to 0.5 ± 0.3 g/g (P < 0.001). At 9 months, 12 patients (92.3%) achieved complete remission, the mean 24-hour UPCR decreased to 0.4 ± 0.1 g/g (Figure 1). Additionally, the renal function of patients remained stable, urinary red blood cells, blood CD4+ T cells, CD19+ B cells, Immunoglobulin levels were decreased compared with the baseline values in all patients at 9 months (Figure 2 and Figure 3). No severe adverse events were observed (Table 2).

Conclusion

Additional telitacicept significantly increased the complete remission rate of IgAVN with persistent proteinuria and stabilized renal function, without serious adverse events.

Kewords